Scott Dreyer sold $848k of COLL
EVP & Chief Commercial Officer at COLLEGIUM PHARMACEUTICAL, INC. 17,600 shares at an average of $48.17, traded Dec 8, 2025, filed Dec 10, 2025.
Score components
- +15RoleOfficer
- +23Trade size$848k at market
- +5Share of holdings soldSold 15% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.8%, 3m -27.1%, 6m -28.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001746251-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | MOption exercise Common Stock10b5-1 | +17,600 | $15.90 | $280k | 121,213 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stock10b5-1 | -11,125 | $47.89 | $533k | 110,088 | Dec 10, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stock10b5-1 | -6,475 | $48.66 | $315k | 103,613 | Dec 10, 2025 |
| Dec 8, 2025 | MOption exercise Stock Option (Right to Purchase)derivative10b5-1 | -17,600 | $0.00 | $0 | 0 | Dec 10, 2025 |
Related signals
Other insiders at COLLEGIUM PHARMACEUTICAL, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | COLLEGIUM PHARMACEUTICAL, INC | John Gordon Freund director | $681 20 shares | -0% | |
| 26Weak | COLLEGIUM PHARMACEUTICAL, INC | John Gordon Freund director | $143k 4,127 shares | -5% | |
| 46Moderate | COLLEGIUM PHARMACEUTICAL, INC | Nancy Lurker director | $162k 4,500 shares | -20% | |
| 34Weak | COLLEGIUM PHARMACEUTICAL, INC | Garen G Bohlin director | $323k 8,700 shares | -12% | |
| 18Weak | COLLEGIUM PHARMACEUTICAL, INC | David Dieter EVP & General Counsel | $488k 13,976 shares | -15% | |
| 16Weak | COLLEGIUM PHARMACEUTICAL, INC | David Dieter EVP & General Counsel | $228k 6,224 shares | -6% | |
| 38Weak | COLLEGIUM PHARMACEUTICAL, INC | Scott Dreyer EVP & Chief Commercial Officer | $2.0M 49,976 shares | -41% | |
| 34Weak | COLLEGIUM PHARMACEUTICAL, INC | Rita J. Balice-Gordon director | $172k 3,650 shares | -6% | |
| 43Moderate | COLLEGIUM PHARMACEUTICAL, INC | John A. Fallon director | $1.6M 34,853 shares | -35% | |
| 40Moderate | COLLEGIUM PHARMACEUTICAL, INC | Colleen Tupper EVP & Chief Financial Officer | $1.2M 30,000 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.